Log in
Enquire now
‌

p16 Methylation for Smoking Cessation

OverviewStructured DataIssuesContributors

Contents

clinicaltrials.gov/study/NCT01038492
Is a
‌
Clinical study
0

Clinical Study attributes

NCT Number
NCT010384920
Health Conditions in Trial
Lung cancer
Lung cancer
0
‌
Smoking cessation
0
Trial Recruitment Size
350
Trial Sponsor
Duke University
Duke University
0
Trial Collaborator
‌
Cancer and Leukemia Group B
0
Clinical Trial Start Date
2009
0
Primary Completion Date
2010
0
Study Completion Date
2010
0
Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Diagnostic0
Intervention Type
Behavioral0
Interventional Trial Phase
Not Applicable0
Official Name
Testing the Feasibility of Using an Epigenetic Marker, p16, to Promote Smoking Cessation0
Last Updated
June 28, 2013
0
Allocation Type
NA0
Intervention Model
Single Group Assignment0
Masking Type
None (Open Label)0

Other attributes

Intervention Treatment
p16 Methylation and Lung Cancer Education0
Study summary

Smoking cessation is often difficult for smokers to achieve for a variety of reasons including: difficulty with nicotine withdrawal, failure to perceive the benefits of smoking cessation, and failure to perceive the risks associated with smoking. We argue that the most effective biomarkers to affect perceptions of harm, especially for lung cancer, are those that signal progression towards disease development Proposed is a pilot study of educating smokers about the role of genetics and lung cancer in Durham VA out-patient clinics. The goal of this pilot study is to assess the interest in study participation from the VA smoking population, as well as to determine the fraction of subjects who will complete the study to power a future larger trial. Interested patients will receive a 15 minute educational presentation on the function of p16 and its role in development of lung cancer. They will then be assessed for airway obstruction by hand-held spirometry followed by review of a questionnaire assessing their understanding of the presented information, their concern for developing lung cancer, and their desire to quit smoking. All patients will be offered smoking cessation assistance at this point. Enrolled patients will then be given 3 sputum cups to take home and return with morning sputum samples by mail. Samples will be assessed for evidence of p16 methylation and patients will be informed of the results. Follow-up phone interviews will be performed at 2 to 4 weeks after patients have received their results by mail to assess their understanding of the results, and their desire to stop smoking. A final phone interview will occur approximately 3 months after the sputum testing to assess attempts to stop smoking as well as the patients continued understanding of their test results. For purposes of this pilot, we are interested primarily in the descriptive statistics (e.g., frequencies) associated with the outcome of each objective (e.g., how many expressed interest, how many returned the sputum samples).

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like p16 Methylation for Smoking Cessation

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.